Theranostic applications of nanoparticles in neurodegenerative disorders

References

• The Royal Society & The Royal Academy of EngineeringNanomanufacturing and the industrial application of nanotechnologies2004 Available from: http://www.nanotec.org.uk/report/chapter4.pdfAccessed June 12, 2018
   Google Scholar
• NeuweltEABauerBFahlkeCEngaging neuroscience to advance translational research in brain barrier biologyNat Rev Neurosci201112316918221331083
   PubMed Web of Science ®Google Scholar
• WekslerBBSubileauEAPerrièreNBlood-brain barrier-specific properties of a human adult brain endothelial cell lineFASEB J200519131872187416141364
   PubMed Web of Science ®Google Scholar
• DavsonHSegalMBPhysiology of the CSF and Blood-Brain BarriersBoca RatonCRC Press199611
   Google Scholar
• BolognesiMLFrom imaging agents to theranostic drugs in Alzheimer’s disease Reference Module in Chemistry, Molecular Sciences and Chemical EngineeringNew YorkElsevier201774106
   Google Scholar
• SikkandharMGNedumaranAMRavichandarRTheranostic probes for targeting tumor microenvironment: an overviewInt J Mol Sci2017185E103628492519
   PubMed Web of Science ®Google Scholar
• SridharSMishraSGulyásMPadmanabhanPGulyásBAn overview of multimodal neuroimaging using nanoprobesInt J Mol Sci2017182311
   PubMed Web of Science ®Google Scholar
• Moreno-GonzalezISotoCMisfolded protein aggregates: Mechanisms, structures and potential for disease transmissionSemin Cell Dev Biol201122548248721571086
   PubMed Web of Science ®Google Scholar
• SweeneyPParkHBaumannMProtein misfolding in neurodegenerative diseases: implications and strategiesTransl Neurodegener201761628293421
   PubMed Web of Science ®Google Scholar
• BegleyDJKreuterJDo ultra-low frequency (ULF) magnetic fields affect the blood-brain barrier?HolickMFJungEGBiologic Effects of Light 1998Boston, MASpringer US1999297301
   Google Scholar
• Juillerat-JeanneretLThe targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?Drug Discov Today20081323–241099110618848640
   PubMed Web of Science ®Google Scholar
• BegleyDJBrightmanMWStructural and functional aspects of the blood-brain barrierProg Drug Res200361397814674608
   PubMedGoogle Scholar
• OlivierJ-CDrug transport to brain with targeted nanoparticlesNeuroRx20052110811915717062
   PubMedGoogle Scholar
• GabathulerRApproaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseasesNeurobiol Dis2010371485719664710
   PubMed Web of Science ®Google Scholar
• HansMLLowmanAMBiodegradable nanoparticles for drug delivery and targetingCurr Opin Solid State Mater Sci200264319327
   Web of Science ®Google Scholar
• PersidskyYRamirezSHHaorahJKanmogneGDBlood-brain barrier: structural components and function under physiologic and pathologic conditionsJ Neuroimmune Pharmacol20061322323618040800
   PubMed Web of Science ®Google Scholar
• SinghRLillardJWNanoparticle-based targeted drug deliveryExp Mol Pathol200986321522319186176
   PubMed Web of Science ®Google Scholar
• ChoiHSLiuWMisraPRenal clearance of nanoparticlesNat Biotechnol20072510116517891134
   PubMed Web of Science ®Google Scholar
• BhadraDBhadraSJainPJainNPegnology: a review of PEG-ylated systemsPharmazie200257152911836932
   PubMed Web of Science ®Google Scholar
• WilsonBSamantaMKSanthiKKumarKPSParamakrishnanNSureshBPoly (n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s diseaseBrain Res2008120015916818291351
   PubMed Web of Science ®Google Scholar
• ChungHChoiHKimDJeongSKimJSize dependence of excitation-energy-related surface trapping dynamics in PbS quantum dotsJ Phys Chem C20151191375177524
   Web of Science ®Google Scholar
• BormPJRobbinsDHauboldSThe potential risks of nano-materials: a review carried out for ECETOCPart Fibre Toxicol200631116907977
   PubMed Web of Science ®Google Scholar
• RodunerESize matters: why nanomaterials are differentChem Soc Rev200635758359216791330
   PubMed Web of Science ®Google Scholar
• DasGKZhangYD’SilvaLSingle-phase Dy2O3:Tb3+ nanocrystals as dual-modal contrast agent for high field magnetic resonance and optical imagingChem Mater201123924392446
   Web of Science ®Google Scholar
• JanibSMMosesASMacKayJAImaging and drug delivery using theranostic nanoparticlesAdv Drug Deliv Rev201062111052106320709124
   PubMed Web of Science ®Google Scholar
• ChenZSmall-molecule delivery by nanoparticles for anticancer therapyTrends Mol Med2010161259460220846905
   PubMed Web of Science ®Google Scholar
• LiWLuoRLinXRemote modulation of neural activities via near-infrared triggered release of biomoleculesBiomaterials201565768526142778
   PubMed Web of Science ®Google Scholar
• MüllerRHJacobsCKayserONanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the futureAdv Drug Deliv Rev200147131911251242
   PubMed Web of Science ®Google Scholar
• WilsonBSamantaMKSanthiKKumarKPSParamakrishnanNSureshBTargeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticlesEur J Pharm Biopharm2008701758418472255
   PubMed Web of Science ®Google Scholar
• KulkarniPVRoneyCAAntichPPBonteFJRaghuAVQuinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s diseaseWiley Interdiscip Rev Nanomed Nanobiotechnol201021354720049829
   PubMed Web of Science ®Google Scholar
• WilsonBSamantaMKSanthiKKumarKPSRamasamyMSureshBChitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrineNanomedicine201061744750
   Web of Science ®Google Scholar
• ZhaoXLiFLiYCo-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancerBiomaterials201546132525678112
   PubMed Web of Science ®Google Scholar
• OsminkinaLANikolaevALSviridovAPPorous silicon nanoparticles as efficient sensitizers for sonodynamic therapy of cancerMicroporous Mesoporous Mater2015210169175
   Web of Science ®Google Scholar
• ZhaoLZhouYGaoYBovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicityInt J Pharm20154831–218018725681723
   PubMedGoogle Scholar
• HallerELindnerWLämmerhoferMGold nanoparticle-antibody conjugates for specific extraction and subsequent analysis by liquid chromatography-tandem mass spectrometry of malondialdehyde-modified low density lipoprotein as biomarker for cardiovascular riskAnal Chim Acta2015857536325604820
   PubMed Web of Science ®Google Scholar
• FuYCFuTFWangHJAspartic acid-based modified PLGA-PEG nanoparticles for bone targeting: in vitro and in vivo evaluationActa Biomater201410114583459625050775
   PubMed Web of Science ®Google Scholar
• KumarGSKulkarniAKhuranaAKaurJTikooKSelenium nanoparticles involve HSP-70 and SIRT1 in preventing the progression of type 1 diabetic nephropathyChem Biol Interact201422312513325301743
   PubMed Web of Science ®Google Scholar
• MiguelLNoirayMSurpateanuGIorgaBIPonchelGDe & Poly (γ-benzyl-l-glutamate)-PEG-alendronate multivalent nanoparticles for bone targetingInt J Pharm20144601–2738224211357
   PubMedGoogle Scholar
• YilmazARöschSKlingelKMagnetic resonance imaging (MRI) of inflamed myocardium using iron oxide nanoparticles in patients with acute myocardial infarction – preliminary resultsInt J Cardiol2013163217518221689857
   PubMed Web of Science ®Google Scholar
• BadrGAl-SadoonMKRabahDMTherapeutic efficacy and molecular mechanisms of snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles in the treatment of breast cancer- and prostate cancer-bearing experimental mouse modelsFree Radic Biol Med20136517518923811005
   PubMed Web of Science ®Google Scholar
• GaoYGuWChenLXuZLiYThe role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseasesBiomaterials200829304129413618667234
   PubMed Web of Science ®Google Scholar
• KaurIPBhandariRBhandariSKakkarVPotential of solid lipid nanoparticles in brain targetingJ Control Release200812729710918313785
   PubMed Web of Science ®Google Scholar
• FarajiAHWipfPNanoparticles in cellular drug deliveryBioorg Med Chem20091782950296219299149
   PubMed Web of Science ®Google Scholar
• KreuterJRamgePPetrovVDirect evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticlesPharm Res200320340941612669961
   PubMed Web of Science ®Google Scholar
• VolicerLManagement of severe Alzheimer’s disease and end-of-life issuesClin Geriatr Med200117237739111375141
   PubMed Web of Science ®Google Scholar
• ForchettiCMTreating Patients With Moderate to Severe Alzheimer’s Disease: Implications of Recent Pharmacologic StudiesPrim Care Companion J Clin Psychiatry20057415516116163398
   PubMedGoogle Scholar
• SelkoeDJSchenkDAlzheimer’s disease: molecular understanding predicts amyloid-based therapeuticsAnnu Rev Pharmacol Toxicol200343154558412415125
   PubMed Web of Science ®Google Scholar
• MahmoudiMShokrgozarMAMultifunctional stable fluorescent magnetic nanoparticlesChem Commun2012483339573959
   PubMed Web of Science ®Google Scholar
• HelznerEPScarmeasNCosentinoSTangMXSchupfNSternYSurvival in Alzheimer disease: a multiethnic, population-based study of incident casesNeurology200871191489149518981370
   PubMed Web of Science ®Google Scholar
• XieJBrayneCMatthewsFEMedical Research Council Cognitive Function and Ageing Study CollaboratorsSurvival times in people with dementia: analysis from population based cohort study with 14 year follow-upBMJ2008336763825826218187696
   PubMed Web of Science ®Google Scholar
• AllinsonTMParkinETTurnerAJHooperNMADAMs family members as amyloid precursor protein alpha-secretasesJ Neurosci Res200374334235214598310
   PubMed Web of Science ®Google Scholar
• DicksonDWCrystalHABevonaCHonerWVincentIDaviesPCorrelations of synaptic and pathological markers with cognition of the elderlyNeurobiol Aging19951632852987566338
   PubMed Web of Science ®Google Scholar
• TerryRDMasliahESalmonDPPhysical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairmentAnn Neurol19913045725801789684
   PubMed Web of Science ®Google Scholar
• BegleyDJDelivery of therapeutic agents to the central nervous system: the problems and the possibilitiesPharmacol Ther20041041294515500907
   PubMed Web of Science ®Google Scholar
• RoneyCKulkarniPAroraVTargeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer’s diseaseJ Control Release2005108219321416246446
   PubMed Web of Science ®Google Scholar
• TanifumEADasguptaISrivastavaMIntravenous delivery of targeted liposomes to amyloid-β pathology in APP/PSEN1 transgenic micePLoS One2012710e4851523119043
   PubMed Web of Science ®Google Scholar
• CuiZLockmanPRAtwoodCSNovel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s and other CNS diseasesEur J Pharm Biopharm200559226327215661498
   PubMed Web of Science ®Google Scholar
• AgyareEKCurranGLRamakrishnanMYuCCPodusloJFKandimallaKKDevelopment of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer’s disease and cerebral amyloid angiopathyPharm Res200825112674268418712585
   PubMed Web of Science ®Google Scholar
• BastusNGKoganMJAmigoRGold nanoparticles for selective and remote heating of β-amyloid protein aggregatesMater Sci Eng C2007275–812361240
   Google Scholar
• ZhangCChenJFengCIntranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer’s diseaseInt J Pharm20144611–219220224300213
   PubMedGoogle Scholar
• ZhangCWanXZhengXDual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer’s disease miceBiomaterials201435145646524099709
   PubMed Web of Science ®Google Scholar
• LiYXuDHoSLLiHWYangRWongMSA theranostic agent for in vivo near-infrared imaging of β-amyloid species and inhibition of β-amyloid aggregationBiomaterials201694849227107167
   PubMed Web of Science ®Google Scholar
• FisherRSHoJPotential new methods for antiepileptic drug deliveryCNS Drugs200216957959312153331
   PubMed Web of Science ®Google Scholar
• De TiègeXLaufsHBoydSGEEG-fMRI in children with pharmacoresistant focal epilepsyEpilepsia200748238538917295635
   PubMed Web of Science ®Google Scholar
• MoodyWJFutamachiKJPrinceDAExtracellular potassium activity during epileptogenesisExp Neurol19744222482634824976
   PubMed Web of Science ®Google Scholar
• RuteckiPALebedaFJJohnstonDEpileptiform activity induced by changes in extracellular potassium in hippocampusJ Neurophysiol1985545136313742416891
   PubMed Web of Science ®Google Scholar
• HuangWCHuSHLiuKHChenSYLiuDMA flexible drug delivery chip for the magnetically-controlled release of anti-epileptic drugsJ Control Release2009139322122819607866
   PubMed Web of Science ®Google Scholar
• CouvreurPVauthierCNanotechnology: intelligent design to treat complex diseasePharm Res20062371417145016779701
   PubMed Web of Science ®Google Scholar
• BirnbaumDTKosmalaJDBrannon-PeppasLOptimization of preparation techniques for poly(lactic acid-co-glycolic acid) nanoparticlesJ Nanoparticle Res200022173181
   Web of Science ®Google Scholar
• ItoFFujimoriHMakinoKIncorporation of water-soluble drugs in PLGA microspheresColloids Surf B Biointerfaces200754217317817137764
   PubMed Web of Science ®Google Scholar
• FrieseASeillerEQuackGLorenzBKreuterJIncrease of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly (butylcyanoacrylate) nanoparticles as a parenteral controlled release systemEur J Pharm Biopharm200049210310910704892
   PubMed Web of Science ®Google Scholar
• YingXWangYLiangJAngiopep-conjugated electro-responsive hydrogel nanoparticles: therapeutic potential for epilepsyAngew Chem Int Ed Engl20145346124361244025044856
   PubMed Web of Science ®Google Scholar
• HsiaoMHLarssonMLarssonADesign and characterization of a novel amphiphilic chitosan nanocapsule-based thermo-gelling biogel with sustained in vivo release of the hydrophilic anti-epilepsy drug ethosuximideJ Control Release2012161394294822652548
   PubMed Web of Science ®Google Scholar
• FuTKongQShengHGaoLValue of functionalized superpara-magnetic iron oxide nanoparticles in the diagnosis and treatment of acute temporal lobe epilepsy on MRINeural Plast20162016241295826925269
   PubMed Web of Science ®Google Scholar
• SinghNPillayVChoonaraYEAdvances in the treatment of Parkinson’s diseaseProg Neurobiol2007811294417258379
   PubMed Web of Science ®Google Scholar
• JohnstonTHFoxSHBrotchieJMAdvances in the delivery of treatments for Parkinson’s diseaseExpert Opin Drug Deliv2005261059107316296809
   PubMedGoogle Scholar
• KatzenschlagerRHughesAEvansAContinuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challengesMov Disord200520215115715390035
   PubMed Web of Science ®Google Scholar
• NyholmDNilsson RemahlAIDizdarNDuodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson diseaseNeurology200564221622315668416
   PubMed Web of Science ®Google Scholar
• BennettJPPierceyMFPramipexole – a new dopamine agonist for the treatment of Parkinson’s diseaseJ Neurol Sci19991631253110223406
   PubMed Web of Science ®Google Scholar
• PatilRRYuJBanerjeeSRProbing in vivo trafficking of polymer/DNA micellar nanoparticles using SPECT/CT imagingMol Ther20111991626163521750533
   PubMed Web of Science ®Google Scholar
• ObesoJARodriguez-OrozMCGoetzCGMissing pieces in the Parkinson’s disease puzzleNat Med201016665366120495568
   PubMed Web of Science ®Google Scholar
• MenaMAGarcía de YébenesJGlial cells as players in parkinsonism: the “good,” the “bad,” and the “mysterious” gliaNeuroscientist200814654456019029058
   PubMed Web of Science ®Google Scholar
• OrrCFRoweDBHallidayGMAn inflammatory review of Parkinson’s diseaseProg Neurobiol200268532534012531233
   PubMed Web of Science ®Google Scholar
• FiandacaMSForsayethJRDickinsonPJBankiewiczKSImage-guided convection-enhanced delivery platform in the treatment of neurological diseasesNeurotherapeutics20085112312718164491
   PubMed Web of Science ®Google Scholar
• NeuweltEAMechanisms of disease: the blood-brain barrierNeurosurgery200454113113214683550
   PubMed Web of Science ®Google Scholar
• KlejborIStachowiakEKBharaliDJORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathologyJ Neurosci Methods2007165223024317655935
   PubMed Web of Science ®Google Scholar
• YurekDMFlectcherAMKowalczykTHPadegimasLCooperMJCompacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neuronsCell Transplant20091810–111183119619650971
   PubMed Web of Science ®Google Scholar
• WenZYanZHuKOdorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administrationJ Control Release2011151213113821362449
   PubMed Web of Science ®Google Scholar
• HuKShiYJiangWHanJHuangSJiangXLactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson’s diseaseInt J Pharm20114151–227328321651967
   PubMed Web of Science ®Google Scholar
• MorrisonPJAccurate prevalence and uptake of testing for Huntington’s diseaseLancet Neurol20109121147
   PubMed Web of Science ®Google Scholar
• PringsheimTWiltshireKDayLDykemanJSteevesTJetteNThe incidence and prevalence of Huntington’s disease: a systematic review and meta-analysisMov Disord20122791083109122692795
   PubMed Web of Science ®Google Scholar
• WexlerNSLorimerJPorterJU.S.-Venezuela Collaborative Research ProjectVenezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onsetProc Natl Acad Sci U S A2004101103498350314993615
   PubMed Web of Science ®Google Scholar
• ZuccatoCCattaneoEHuntington’s DiseaseLewinGCarterBNeurotrophic Factors Handbook of Experimental Pharmacology220Berlin, HeidelbergSpringer2014
   Google Scholar
• RossCATabriziSJHuntington’s disease: from molecular pathogenesis to clinical treatmentLancet Neurol2011101839821163446
   PubMed Web of Science ®Google Scholar
• MacDonaldMEAmbroseCMDuyaoMPA novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomesCell19937269719838458085
   PubMed Web of Science ®Google Scholar
• SandhirRYadavAMehrotraASunkariaASinghASharmaSCurcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington’s diseaseNeuromolecular Med201416110611824008671
   PubMed Web of Science ®Google Scholar
• BhattRSinghDPrakashAMishraNDevelopment, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington’s diseaseDrug Deliv201522793193924512295
   PubMed Web of Science ®Google Scholar